Haploidentical transplantation for leukemia

Current Oncology Reports

Volumn 12, Issue 5, 2010, Pages 292-301

  Kanda, Junya ^a   Chao, Nelson J ^a   Rizzieri, David A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Donor lymphocyte infusion; Haploidentical transplantation; Immune recovery; Interleukin 2; KIR ligand mismatch; NK cell infusion; T cell depletion method

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CELL RECEPTOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUDARABINE; INTERLEUKIN 2; KILLER INHIBITORY RECEPTOR; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; SEMUSTINE; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; HLA ANTIGEN;

ACUTE LEUKEMIA; BLOOD DONOR; CARCINOMA; CLONAL ANERGY; DONOR LYMPHOCYTE INFUSION; DONOR SELECTION; ENGRAFTMENT; GRAFT VERSUS HOST REACTION; HAPLOIDENTICAL STEM CELL TRANSPLANTATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOLOGICAL TOLERANCE; INFECTION RATE; LEUKEMIA; MYELOABLATIVE CONDITIONING; NATURAL KILLER CELL; NONHUMAN; PATIENT SAFETY; PLACENTAL TRANSFER; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; REVIEW; RISK REDUCTION; STEM CELL TRANSPLANTATION; T CELL DEPLETION; T LYMPHOCYTE SUBPOPULATION; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; CLINICAL TRIAL (TOPIC); GRAFT SURVIVAL; HISTOCOMPATIBILITY; METABOLISM;

CLINICAL TRIALS AS TOPIC; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; LEUKEMIA; TRANSPLANTATION, HOMOLOGOUS;

EID: 77956268107     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0113-4     Document Type: Review

References (55)

1. C Anasetti PG Beatty R Storb, et al. 1990 Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma Hum Immunol 29 79 91 10.1016/0198-8859(90)90071-V 1:STN:280:DyaK3M%2FmsFyhsQ%3D%3D 2249952
2. I Yakoub-Agha F Mesnil M Kuentz, et al. 2006 Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy J Clin Oncol 24 5695 5702 10.1200/JCO.2006.08.0952 17116940
3. MJ Laughlin M Eapen P Rubinstein, et al. 2004 Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia N Engl J Med 351 2265 2275 10.1056/NEJMoa041276 1:CAS:528:DC%2BD2cXhtValsbzO 15564543
4. GD Long M Laughlin B Madan, et al. 2003 Unrelated umbilical cord blood transplantation in adult patients Biol Blood Marrow Transplant 9 772 780 10.1016/j.bbmt.2003.08.007 14677117
5. Y Reisner N Kapoor D Kirkpatrick, et al. 1981 Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells Lancet 2 327 331 10.1016/S0140-6736(81)90647-4 1:STN:280:DyaL3M3mvFCisg%3D%3D 6115110
6. RH Buckley SE Schiff RI Schiff, et al. 1999 Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency N Engl J Med 340 508 516 10.1056/NEJM199902183400703 1:STN:280:DyaK1M7jsVShsg%3D%3D 10021471
7. RJ O'Reilly C Keever NA Kernan, et al. 1987 HLA nonidentical T cell depleted marrow transplants: a comparison of results in patients treated for leukemia and severe combined immunodeficiency diseases Transplant Proc 19 55 60 3321647
8. HG Prentice HA Blacklock G Janossy, et al. 1982 Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia Lancet 1 700 703 10.1016/S0140-6736(82)92619-8 1:STN:280:DyaL387nt1SgtQ%3D%3D 6122004
9. J Patterson HG Prentice MK Brenner, et al. 1986 Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation Br J Haematol 63 221 230 10.1111/j.1365-2141.1986.tb05544.x 1:STN:280:DyaL283ktlWmtg%3D%3D 3521712
10. F Aversa A Tabilio A Terenzi, et al. 1994 Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum Blood 84 3948 3955 1:STN:280:DyaK2M%2Fjs1ejtA%3D%3D 7524753
11. F Aversa A Tabilio A Velardi, et al. 1998 Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype N Engl J Med 339 1186 1193 10.1056/NEJM199810223391702 1:STN:280:DyaK1cvkt1yqsw%3D%3D 9780338
12. F Aversa A Terenzi A Tabilio, et al. 2005 Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse J Clin Oncol 23 3447 3454 10.1200/JCO.2005.09. 117 15753458
13. PJ Henslee-Downey SH Abhyankar RS Parrish, et al. 1997 Use of partially mismatched related donors extends access to allogeneic marrow transplant Blood 89 3864 3872 1:CAS:528:DyaK2sXjtlSnsL8%3D 9160695
14. J Mehta S Singhal AP Gee, et al. 2004 Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients Bone Marrow Transplant 33 389 396 10.1038/sj.bmt.1704391 1:CAS:528:DC%2BD2cXhvFWjtLc%3D 14716338
15. DP Lu L Dong T Wu, et al. 2006 Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation Blood 107 3065 3073 10.1182/blood-2005-05-2146 1:CAS:528:DC%2BD28Xjs1OlurY%3D 16380454
16. XJ Huang DH Liu KY Liu, et al. 2009 Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation Biol Blood Marrow Transplant 15 257 265 10.1016/j.bbmt.2008.11. 025 1:CAS:528:DC%2BD1MXjtVyiur4%3D 19167686 The authors reported clinical outcome of 250 patients with acute leukemia who underwent a transplant from HLA-mismatched family members by using only in vivo T-cell depletion method and G-CSF-primed bone marrow and peripheral blood
17. Y Kanda K Oshima Y Asano-Mori, et al. 2005 In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation Transplantation 79 1351 1357 10.1097/01.TP.0000158718.49286.14 1:CAS:528:DC%2BD2MXksVajsb8%3D 15912103
18. EC Guinan VA Boussiotis D Neuberg, et al. 1999 Transplantation of anergic histoincompatible bone marrow allografts N Engl J Med 340 1704 1714 10.1056/NEJM199906033402202 1:CAS:528:DyaK1MXjvFCnsLs%3D 10352162
19. JK Davies JG Gribben LL Brennan, et al. 2008 Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies Blood 112 2232 2241 10.1182/blood-2008-03-143636 1:CAS:528:DC%2BD1cXhtFCrurjM 18617635
20. F Ciceri M Labopin F Aversa, et al. 2008 A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation Blood 112 3574 3581 10.1182/blood-2008-02-140095 1:CAS:528:DC%2BD1cXhtlCntrrP 18606875 This is the largest multicenter study, analyzing outcome of 266 patients with acute leukemia who underwent a haploidentical transplantation with the use of myeloablative conditioning regimen and ex vivo T-cell depletion methods
21. WA Bethge M Haegele C Faul, et al. 2006 Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity Exp Hematol 34 1746 1752 10.1016/j.exphem.2006.08.009 1:CAS:528:DC%2BD28Xht12qsrnJ 17157172
22. WA Bethge C Faul M Bornhauser, et al. 2008 Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update Blood Cells Mol Dis 40 13 19 10.1016/j.bcmd.2007.07.001 1:CAS:528:DC%2BD2sXhsVWjsbrI 17869547 The authors updated clinical outcomes of haploidentical transplants with use of ex vivo CD3/CD19 depletion method and reduced-intensity conditioning
23. DA Rizzieri LP Koh GD Long, et al. 2007 Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution J Clin Oncol 25 690 697 10.1200/JCO.2006.07.0953 1:CAS:528:DC%2BD2sXjt1Kgu7c%3D 17228020
24. L Luznik S Jalla LW Engstrom, et al. 2001 Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide Blood 98 3456 3464 10.1182/blood.V98.12. 3456 1:CAS:528:DC%2BD3MXovVSgtrw%3D 11719388
25. PV O'Donnell L Luznik RJ Jones, et al. 2002 Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide Biol Blood Marrow Transplant 8 377 386 10.1053/bbmt.2002.v8.pm12171484 12171484
26. L Luznik PV O'Donnell HJ Symons, et al. 2008 HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide Biol Blood Marrow Transplant 14 641 650 10.1016/j.bbmt.2008.03.005 1:CAS:528: DC%2BD1cXnsFyqt7c%3D 18489989 In this study, the authors reported the outcomes of 68 patients who received a haploidentical bone marrow transplant for hematologic diseases using high-dose, posttransplant cyclophosphamide. Low cumulative incidence of acute GVHD and low non-relapse mortality at 1 year are promising
27. H Ogawa K Ikegame S Yoshihara, et al. 2006 Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning Biol Blood Marrow Transplant 12 1073 1084 10.1016/j.bbmt.2006.06.007 17084371
28. P Dutta M Molitor-Dart JL Bobadilla, et al. 2009 Microchimerism is strongly correlated with tolerance to noninherited maternal antigens in mice Blood 114 3578 3587 10.1182/blood-2009-03-213561 1:CAS:528:DC%2BD1MXhtlyjsrrP 19700665
29. JE Mold J Michaelsson TD Burt, et al. 2008 Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero Science 322 1562 1565 10.1126/science.1164511 1:CAS:528:DC%2BD1cXhsVGltb%2FK 19056990
30. JJ van Rood FR Loberiza Jr MJ Zhang, et al. 2002 Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling Blood 99 1572 1577 10.1182/blood.V99.5.1572 11861270
31. T Ichinohe T Uchiyama C Shimazaki, et al. 2004 Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism Blood 104 3821 3828 10.1182/blood-2004-03-1212 1:CAS:528:DC%2BD2cXhtVGltbrN 15280193
32. J Kanda T Ichinohe C Shimazaki, et al. 2009 Long-term survival after HLA-haploidentical SCT from noninherited maternal antigen-mismatched family donors: impact of chronic GVHD Bone Marrow Transplant 44 327 329 10.1038/bmt.2009.18 1:STN:280:DC%2BD1MngvFWktA%3D%3D 19219076
33. HG Ljunggren KJ Malmberg 2007 Prospects for the use of NK cells in immunotherapy of human cancer Nat Rev Immunol 7 329 339 10.1038/nri2073 1:CAS:528:DC%2BD2sXksFeks74%3D 17438573
34. L Ruggeri M Capanni E Urbani, et al. 2002 Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants Science 295 2097 2100 10.1126/science.1068440 1:CAS:528:DC%2BD38Xit1Ohurs%3D 11896281
35. L Ruggeri A Mancusi M Capanni, et al. 2007 Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value Blood 110 433 440 10.1182/blood-2006-07-038687 1:CAS:528:DC%2BD2sXnsVait7c%3D 17371948
36. KC Hsu CA Keever-Taylor A Wilton, et al. 2005 Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes Blood 105 4878 4884 10.1182/blood-2004-12-4825 1:CAS:528:DC%2BD2MXlsVWis7s%3D 15731175
37. RM Sobecks EJ Ball JP Maciejewski, et al. 2007 Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors Bone Marrow Transplant 39 417 424 10.1038/sj.bmt.1705609 1:CAS:528: DC%2BD2sXjt1Wrsrs%3D 17310134
38. A van der Meer NP Schaap AV Schattenberg, et al. 2008 KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients Mol Immunol 45 3631 3638 10.1016/j.molimm.2008.04.016 18555529
39. S Cooley E Trachtenberg TL Bergemann, et al. 2009 Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia Blood 113 726 732 10.1182/blood-2008-07-171926 1:CAS:528:DC%2BD1MXht1Wntr8%3D 18945962
40. Prasad VK, Chen D, Broadwater G, et al.: Differential impact of inhibitory and activating killer Ig-like receptors and HLA ligand on outcomes of transplantation for myeloid and lymphoid malignancies. Blood (ASH Annual Meeting Abstracts) 2008, 112:abstract 3255.
41. M Tomblyn HM Lazarus 2008 Donor lymphocyte infusions: the long and winding road: how should it be traveled? Bone Marrow Transplant 42 569 579 10.1038/bmt.2008.259 1:STN:280:DC%2BD1cjivFSqsg%3D%3D 18711351
42. DA Rizzieri P Dev GD Long, et al. 2009 Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors Bone Marrow Transplant 43 327 333 10.1038/bmt.2008.321 1:CAS:528:DC%2BD1MXit1Krt7s%3D 18850014
43. JR Passweg A Tichelli S Meyer-Monard, et al. 2004 Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation Leukemia 18 1835 1838 10.1038/sj.leu.2403524 1:STN:280:DC%2BD2crjsVartA%3D%3D 15457184
44. •• Rizzieri DA, Storms R, Chen D, et al.: Natural killer cell enriched donor lymphocyte infusions from a 3-6/6 HLA matched family member following non-myeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010, In press. The authors tested the feasibility of infusions of donor NK cells that were collected by using a CD56+ selecting column in 30 HLA-matched/mismatched transplanted patients. They found that NK cell-enriched donor cell infusions resulted in improved immune recovery and outcome for selected patients.
45. Yoon SR, Lee YS, Yang SH, et al.: Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant 2009, In press.
46. PJ Amrolia G Muccioli-Casadei H Huls, et al. 2006 Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation Blood 108 1797 1808 10.1182/blood-2006-02-001909 1:CAS:528:DC%2BD28Xpsl2isrY%3D 16741253
47. Roy DC, Lachance S, Kiss T, et al.: Haploidentical stem cell transplantation: high doses of alloreactie-T cell depleted donor lymphocytes administered post-transplant decrease infections and improve survival without causing severe GVHD. Blood (ASH Annual Meeting Abstracts) 2009, 114:abstract 512.
48. F Ciceri C Bonini MT Stanghellini, et al. 2009 Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study Lancet Oncol 10 489 500 10.1016/S1470-2045(09) 70074-9 19345145 In this phase I-II study, the authors demonstrated the feasibility of infusion of donor lymphocytes expressing herpes simplex thymidine kinase suicide gene after transplantation, and the possible effect of accelerating immune reconstitution
49. BJ Chen X Cui C Liu NJ Chao 2002 Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process Blood 99 3083 3088 10.1182/blood.V99.9.3083 1:CAS:528:DC%2BD38XjtlGru7s%3D 11964269
50. K Perruccio F Topini A Tosti, et al. 2008 Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation Blood Cells Mol Dis 40 76 83 10.1016/j.bcmd.2007.06.022 1:CAS:528:DC%2BD2sXhsVWjsbvP 17977031
51. •• Vago L, Perna SK, Zanussi M, et al.: Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 2009, 361:478-488. The authors found loss of HLA haplotype that differed from the donor's haplotype in leukemic cells of patients who relapsed after haploidentical transplantation and infusion of donor T cells, and provided hypothesis of an interesting mechanism underlying the escape of immune surveillance after haploidentical transplantation.
52. Ianni MD, Falzetti F, Carotti A, et al.: Adoptive immunotherapy with tregs prevents GvHD and favours immune reconstitution after HLA haploidentical transplants for hematological malignancies. Blood (ASH Annual Meeting Abstracts) 2009, 114:abstract 4.
53. U Keilholz C Conradt SS Legha, et al. 1998 Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients J Clin Oncol 16 2921 2929 1:CAS:528:DyaK1cXmtFSls74%3D 9738559
54. SA Rosenberg JC Yang SL Topalian, et al. 1994 Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 JAMA 271 907 913 10.1001/jama.271.12.907 1:STN:280:DyaK2c7ms1Wmsg%3D%3D 8120958
55. JE Rubnitz H Inaba RC Ribeiro, et al. 2010 NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia J Clin Oncol 28 955 959 10.1200/JCO.2009.24.4590 1:CAS:528:DC%2BC3cXktF2ltrw%3D 20085940